UnknownNot Applicable

A Comparison of Invasive and Non-invasive Measurement of CI and SVR in Liver Transplantation

South Korea30 participantsStarted 2021-05-31

Plain-language summary

Patients who are scheduled to receive living donor liver transplantation will be monitored with a radial and femoral arterial line. A pulmonary artery catheter will also be placed and central venous pressure, cardiac index, and cardiac output will also be monitored. Simultaneously, on the middle finger of the hand where the radial artery is monitored, Clearsight (Edwards Lifesciences, Irvine, CA), a finger cuff, is placed and noninvasive blood pressure, cardiac output, cardiac index are measured. Using the VitalDB program, the parameters measured with the invasive methods and the parameters obtained by the noninvasive method are compared.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * routine living donor liver transplantation recipients needing pulmonary artery catheterization who have been informed and given consent Exclusion Criteria: * Patients with atrial fibrillation * Contraindications to pulmonary artery catheterization or needing attention to insertion of pulmonary artery catheter: right-sided endocarditis, tumors, right sided valvular disease, left bundle branch block * Patients with obstructive vascular disease in the upper extremities, anatomical deformities in the upper extremities, Raynaud syndrome, etc.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

comparison of invasive and non-invasive measurement for cardiac index

Timeframe: Phase 1 (preanhepatic1): completion of the anesthetic induction (baseline)

comparison of invasive and non-invasive measurement for systemic vascular resistance

Timeframe: Phase 1 (preanhepatic1): completion of the anesthetic induction (baseline)

comparison of invasive and non-invasive measurement for cardiac index

Timeframe: Phase 2 (preanhepatic2): 60 minutes after the anesthetic induction

comparison of invasive and non-invasive measurement for systemic vascular resistance

Timeframe: Phase 2 (preanhepatic2): 60 minutes after the anesthetic induction

comparison of invasive and non-invasive measurement for cardiac index

Timeframe: Phase 3 (anhepatic 1): 10 minutes after recipient hepatectomy is complete

comparison of invasive and non-invasive measurement for systemic vascular resistance

Timeframe: Phase 3 (anhepatic 1): 10 minutes after recipient hepatectomy is complete

Trial details

NCT IDNCT04909645

SponsorSeoul National University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-05-28

Contact for this trial

Seong Mi Yang

+82-10-7300-6282 seongmi.yang@gmail.com

View on ClinicalTrials.gov More Living Donor Liver Transplantation trials